Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS

Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS

Submitted by admin on November 30, 2018 - 10:21am
Source: 
Pharmaceutical Business Review
News Tags: 
Novartis
Gilenya
Europe
Relapsing Remitting Multiple Sclerosis
Headline: 
Novartis’ Gilenya gets approval in Europe to treat children and adolescents with MS
snippet: 

Novartis has secured approval from the European Commission (EC) for its Gilenya (fingolimod) to treat children and adolescents, aged between 10 and 17 years, with relapsing-remitting forms of multiple sclerosis (RRMS).